

## Special Issue

# Development of Broadly Protective Vaccines Against Respiratory Virus Infections

### Message from the Guest Editors

Respiratory virus infections pose substantial health burdens globally; causing significant morbidity & mortality. Traditional vaccines offer varying degrees of success; however, their strain-specific protection & limited durability show the need for broadly protective vaccines. These vaccines aim to elicit cross-reactive immune responses that protect against multiple virus strains or species. This issue will highlight cutting-edge research & developments in broadly protective vaccines against respiratory viruses. We invite submissions on:

- Strategies for designing broadly protective or universal vaccines.
- Development & optimization of novel vaccine platforms & adjuvants that enhance scope & durability of protection.
- Characterization of cross-protective immune responses, such as broadly neutralizing antibodies, T-cell responses, & mucosal immunity.
- Preclinical & clinical evaluations of vaccine efficacy against diverse respiratory virus strains.
- Factors in developing broadly protective vaccines for vulnerable populations.
- Long-term safety, immunogenicity, & immune correlates of protection for broadly protective vaccine candidates.

We look forward to your valuable contributions.

---

### Guest Editors

Dr. Noopur Bhatnagar

Center for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30302, USA

Prof. Dr. Jerry W. Simecka

Department of Pharmaceutical Sciences and UNTHSC Preclinical Services, University of North Texas System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX, USA

---

### Deadline for manuscript submissions

20 January 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/244244](https://mdpi.com/si/244244)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).